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Combretastatin-A4-phosphate (CA4P) acts most effectively against immature tumour vasculature. We investigated whether
histological angiogenic profile can explain the differential sensitivity of human tumours to CA4P, by correlating the kinetic changes
demonstrated by dynamic MRI (DCE-MRI) in response to CA4P, with tumour immunohistochemical angiogenic markers. Tissue was
received from 24 patients (mean age 59, range 32–73, 18 women, 6 men). An angiogenic profile was performed using standard
immunohistochemical techniques. Dynamic MRI data were obtained for the same patients before and 4 h after CA4P. Three patients
showed a statistically significant fall in Ktrans following CA4P, and one a statistically significant fall in IAUGC60. No statistically significant
correlations were seen between the continuous or categorical variables and the DCE-MRI kinetic parameters other than between
ang-2 and Ktrans (P¼ 0.044). In conclusion, we found no strong relationships between changes in DCE-MRI kinetic variables following
CA4P and the immunohistochemical angiogenic profile.
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Combretastatin-A4-phosphate (CA4P) is a tubulin-binding, selec-
tive vascular disruptive agent (VDA) that causes rapid shutdown of
blood flow to tumours with minimal effects on normal vasculature.
Tumour endothelial cells are often immunohistochemically im-
mature, lacking smooth muscle and pericyte coverage, and more
sensitive to the effects of VDAs probably because the intracellular
cytoskeleton is less developed (Tozer et al, 2005). Our aim was to
determine human tumour vascular maturity using an immuno-
histochemical angiogenic profile, and to study any relationship with
CA4P response assessed by change in DCE-MRI kinetic variables.
We selected antibodies to differentiate immature vascular
endothelium – CD105 (endoglin), CD61 (b3-integrin), a pericyte
marker a-smooth muscle actin (aSMA), a marker of hypoxia
(Glut-1), proliferation marker (Ki-67), and markers associated
with the angiogenic switch (VEGF, PDGFB, angiopoietin-1, and
angiopoietin-2).
MATERIALS AND METHODS
Following ethics approval, patients enrolled in Mount Vernon
phase I CA4P studies (CR-UK PH1/066 & PH1/092) who under-
went DCE-MRI analysis were identified. Records were obtained
from 26 identified patients and tissue was available for 24 patients
(Table 1). A full set of DCE-MRI data was available for 21. Tissue
blocks were coded to conceal patient identity. Sections (4 mm) were
cut onto slides, and stained with the panel of antibodies at
concentrations and with control samples illustrated in Table 2.
Immunohistochemical procedures
All sections were deparaffinised in xylene and rehydrated through
graded alcohols to water.
CD34 and aSMA double staining Dako’s Cytomation Envision
double stain system (K5361) (Dako Ltd., Cambridgeshire, UK), was
used performed according to the manufacturer’s instructions.
Specimens were counterstained using Gills haematoxylin (01500E;
Surgipath Europe Ltd.) for 7 s and washed. The samples were
mounted and cover slipped using Dako Faramount aqueous
mounting medium (S3025).
CD105 We used Dako’s Catalysed Signal Amplification staining
system (K1497) and followed the manufacturer’s instructions
exactly.
VEGF, Ki-67, and Glut-1 Dako’s Universal autostainer (Dako)
was used. Antigen retrieval was performed in 0.01 M citric acid pH
6. Glut-1 and Ki-67 were microwaved for 3 4 min and VEGF for
4 4 min. Optimum antigen retrieval times were determined from
titration experiments.
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Ang-1, Ang-2, PDGF, and CD61
Benchside manual staining procedures were used. Endogenous
peroxidase activity was quenched with 1.5% hydrogen peroxide in
methanol for 10 min. Antigen retrieval was performed by
microwaving in 0.01 M citric acid pH 6 for 10 min (ang-1) and
20 min (ang-2). After washing in Tris-buffered saline tween-20
(TBST) primary antibody was applied as shown in Table 2, and
incubated overnight at 41C. After rinsing in TBST, Dako Envision
anti-rabbit secondary antibody (K5007) with peroxidase was
applied for 30 min. Antigen was developed with diaminobenzidine,
slides counterstained with haematoxylin, dehydrated, cleared, and
mounted. For CD61 and PDGF Vectastain’s mouse IgG normal
horse serum (Vector Labs, Burlingame, CA, USA) diluted in TBS
was applied for 30 min. A horse anti-mouse biotinylated secondary
was then applied, followed by incubation with streptavidin-
peroxidase reagent.
Immunohistochemical profile analysis
Each slide was assessed using a Zeiss Axioskop microscope, with
Visilog 5.0 (Noesis) image capture software. The random field
Table 1 Patient demographics and histologies
Patient ID Patient age Phase I trial Tumour site Histology
Date specimen
taken
CA4P Dose
(mg m2)
01 64 PH1/066 UK
phase I single agent
CA4P
Paratesticular Spindle cell sarcoma 08/1999 52
02 51 Adrenal Carcinoma 06/1993 68
03 65 Uterus Leiomyosarcoma 03/1999 88
04 63 Renal Renal papillary carcinoma 11/1997 40
05 49 Breast Ductal carcinoma 02/1993 68
06 65 Uterus Leiomyosarcoma 11/1982 52
07 71 Rectum 01/1997 52
08 68 Ovary Papillary adenocarcinoma 05/1994 5
09 62 Uterus Leiomyosarcoma 05/1998 88
10 60 Peritoneum Primary peritoneal carcinoma 09/1999 52
11 50 Right tibia Leiomyosarcoma 10/1997 68
12 60 Ovary Papillary serous adenocarcinoma 03/1994 114
13 49 Lung Adenocarcinoma 04/1998 40
14 45 Renal Spindle cell carcinoma 12/1999 114
15 63 08/1999 114
16 73 Ovary Papillary adenocarcinoma 11/1991 88
17 58 11/1998 68
18 58 PH1/092 (A5B7) Colon Adenocarcinoma 05/2003 45
19 60 02/1999 45
20 73 11/2001 45
21 57 PH1/066 Uterus Leiomyosarcoma 07/1998 N/A
22 70 PH1/092 (A5B7) Colon G2 Adenocarcinoma 10/2003 45
23 66 Adenocarcinoma 08/2001 45
24 32 11/2002 45
Table 2 Angiogenic expression antibody profile
Antibody Type of marker Source Concentration
Specificity and non-
specific staining Control sample
CD34 Vascular Novocastra NCL-END 1 : 60 Endothelium, connective
tissue, erythrocytes
Tonsil
aSMA Sigma A2547 1 : 20000 Smooth muscle Tonsil
CD105 Dako M3527 1 : 1000 Proliferating endothelium,
activated macrophages
Human breast
carcinoma
CD61 Novocastra NCL-CD61-
308
1 : 100 Endothelium, platelets,
megakaryocytes,
monocytes, macrophages
Tonsil, human placenta
VEGF Neomarkers MS-1467 1 : 100 121,165, 189 Isoforms Human breast
carcinoma
Ki-67 Proliferation Dako M7240 1 : 200 345, 395 Isoforms. nuclear
expression
Tonsil
Glut-1 Hypoxia Dako A3536 1 : 200 Erythrocytes, tumour Tonsil
PDGF Vascular/tumour/
stromal
Novocastra NCL-PDEGF
P-GF.44c
1 : 60 Tumour, macrophages,
stroma, glia, epithelia
Tonsil, human placenta
Angiopoietin -1 Santa Cruz Biotech Inc.
H-98 (sc-8357)
1 : 50 Tumour, myocardium,
vascular smooth muscle,
lung, liver
Human placenta
Angiopoietin -2 Santa Cruz Biotech Inc.
H-70 (sc-20718)
1 : 50 Tumour, ovary, placenta,
uterus
Human placenta
SMAa¼ a-smooth muscle actin.
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techniques described by Eberhard et al (2000) were used. Any
CD34þ endothelial cells that were distinctly separate from other
microvessels at high power were considered individual vessels, and
recorded as the number of vessels per high power field. aSMA
staining was analysed concurrently – any CD34þ vessel also
aSMAþ was recorded. Mean microvessel density (MVD per mm2)
and pericyte coverage index (PCI) were calculated after analysing
at least 20 random fields per slide (Table 3). To determine the
Ki-67 proliferation index (%) or Glut-1 hypoxia index (%) each
slide was scanned at low and high magnification. A semiquanti-
tative visual assessment was made across the slide of the
proportion of tumour cells staining positively (Table 3).
The following antigens were analysed using a categorical scale,
with the proportion of immunoreactive cells graded as weak,
moderate, or strong by direct visual assessment at low ( 50) and
high ( 400) magnification (Table 3). The most appropriate cutoff
values were selected from previous studies; VEGF: absent (o5%),
weak (5–25%), moderate (25– 50%), and strong (450%) (Erdem
et al. 2007); Ang-1/2: cytoplasmic expression predominantly and
grading system as for VEGF (Lind et al, 2005); PDGF: highly
expressed in stroma; absent (o1% tumour staining), weak
(1–10%), moderate (10–25%), and strong (425%) (Barnhill
et al, 1996).
Random results were checked by an experienced immuno-
histochemist (FD), who had not seen the initial data. In case of
disagreement as to the correct result, that slide was analysed by a
consultant histopathologist.
DCE-MRI data
DCE-MRI involves the rapid acquisition of sets of T1-weighted
images through tumour as an intravenous bolus of contrast agent
is injected. The change in signal intensity over time can be
analysed with mathematical models (Tofts, 1997). Quantitative
kinetic variables are derived that provide information about
tumour microcirculation as they are indirectly related to perfusion,
vascular permeability, and vessel surface area (d’Arcy et al, 2006).
The IAUGC (initial area under the gadolinium concentration–
time curve – units: mM min) is calculated for the first 60 s following
Gd-DTPA injection (Evelhoch, 1999; Evelhoch et al, 2004). It has
the advantage of being a quantitative variable that is obtained
without mathematical modelling or knowledge of the arterial input
function. It is a measure of how much contrast agent is taken up by
the tumour in the first 60 s post-Gd-DTPA injection and is
influenced by tumour blood flow rate and tumour vessel
permeability. By using AUC from the Gd-DTPA concentration
time curve rather than from the signal intensity time curve, the
problem of dependence of signal enhancement on tissue T1 levels
is avoided.
The transfer constants for Gd-DTPA diffusion into the tumour
extravascular extracellular space (EES) from blood plasma (Ktrans)
and back again (kep) can be calculated using Tofts’ mathematical
model (Tofts and Kermode, 1991; Tofts et al, 1999). Ktrans (and kep)
have both blood flow rate and permeability components as
Gd-DTPA is not freely diffusible and their biological meaning is
dependent on the balance between capillary permeability and
blood flow in the tissue of interest. In high permeability tissues,
Ktrans is equal to the blood plasma flow per unit volume of tissue.
In low permeability tissues such as the brain, it is equal to the
permeability surface area product between the blood plasma and
the EES per unit volume of tissue (Tofts, 1997). In most tumours
the situation is likely to be somewhere between these two extremes.
Studies were performed on a 1.5 T scanner as previously
described (Galbraith et al, 2003). Images were analysed using
specialist software (Magnetic Resonance Imaging Workbench
(MRIW), Institute of Cancer Research, London) (d’Arcy et al,
2006). A dynamic analysis was performed using MRIW for each
pixel within the region of interest on each slice. The MRIW
converts signal intensities of the T1-weighted DCE-MRI data set
into T1 relaxation rates and then into Gd-DTPA concentrations for
individual voxels, using the methods described by Parker et al
(1997). Standardised terms were employed as defined in Tofts et al
(1999). The percentage change from mean baseline kinetic
variables following CA4P was calculated (Table 4).
Table 3 Results–angiogenic expression profile of 24 human tumours
Patient ID
CD34 MVD
per mm2
SMA PCI
(%)
CD105 MVD
per mm2 VEGF
Ki-67
(%)
Glut-1
(%) Ang-1 Ang-2 PDGF
CD61 MVD
per mm2
01 153.67 31.70 6.88 0 ND 0.5 ND ND ND ND
02 96.33 66.85 20.64 1 0.5 1.0 3 1 0 47.02
03 182.34 54.58 64.22 0 20.0 0.5 1 2 0 18.35
04 97.48 85.73 53.90 2 15.0 15.0 2 3 2 19.50
05 127.29 73.69 57.34 2 30.0 10.0 1 2 0 26.38
06 26.38 47.50 13.76 0 1.0 1.0 3 3 0 11.47
07 157.11 50.99 11.47 1 10.0 1.0 1 1 0 19.50
08 92.89 24.67 5.73 1 15.0 20.0 1 1 0 9.17
09 137.61 59.03 10.32 0 10.0 1.0 2 1 0 17.20
10 96.33 41.54 38.99 2 50.0 30.0 0 2 1 43.58
11 151.38 72.51 59.63 0 2.0 0.5 1 2 0 10.32
12 60.78 55.58 19.50 2 40.0 30.0 0 1 0 6.88
13 83.72 57.14 10.32 2 5.0 0.5 1 1 0 1.15
14 160.55 20.53 76.83 2 10.0 5.0 1 2 0 29.82
15 150.23 30.60 30.96 1 15.0 25.0 1 3 0 19.50
16 110.09 77.43 27.52 0 15.0 1.0 2 1 2 11.47
17 123.85 57.90 29.82 2 20.0 5.0 2 3 0 5.73
18 65.37 66.37 24.08 3 60.0 20.0 1 3 0 16.06
19 128.44 44.58 16.06 2 30.0 10.0 1 2 0 24.08
20 90.60 80.15 26.38 2 30.0 5.0 2 2 0 6.88
21 79.13 32.63 36.70 3 1.0 60.0 1 3 1 27.52
22 82.57 79.83 11.47 2 40.0 25.0 2 2 0 9.17
23 142.09 60.85 3.40 3 40.0 2.0 1 1 0 8.52
24 178.90 53.00 73.39 2 25.0 15.0 3 3 1 12.61
MVD¼microvessel density; ND¼ not done, due to lack of available tumour tissue; PCI¼ pericyte coverage index. For the categorical variables, 0¼ negative; 1¼weak
expression; 2¼moderate expression; 3¼ strong expression.
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Statistical analysis
Measurement error (Bland and Altman, 1996) was used to define
confidence intervals for the DCE-MRI variables. Linear regression
and correlation analysis were used to test for relationships between
the continuous variables and MRI data. Analysis of Variance was
used to test for relationships between categorical variables and
MRI data.
RESULTS
Tissue was received from 24 patients (mean age 59, range 32 –73,
18 women, 6 men). Eighteen patients were taken from the PH1/066
single agent UK CA4P trial (Rustin et al, 2003), and 6 from the
PH1/092 CA4Pþ anti-CEA antibody study (Gaya AM et al, 2008,
unpublished). The most common histological subtypes (Table 1)
were colorectal adenocarcinoma (7), uterine leiomyosarcoma (4),
and ovarian adenocarcinoma (3). The age of the tumour blocks
varied between 6 months and 21 years. All but one block contained
primary tumour from surgical specimens, not metastatic tissue as
patients were not rebiopsied before entrance to the phase I trials.
We only studied patients who received doses of CA4P between
40 and 114 mg m2 that have been associated with changes in
DCE-MRI kinetic variables.
There was a wide range of DCE-MRI variable change following
CA4P (Table 4). Percentage change in Ktrans from mean baseline
following CA4P varied between þ 111 and 75%, and IAUGC60
between þ 186 and 90%. In reality, only falls in these parameters
(consistent with tumour vascular shutdown) are clinically
significant. The 95% confidence interval for Ktrans change
(determined from repeatability analysis in the individual studies
and repeated with the combined data) was 62.5 to þ 166.5%,
IAUGC60±80%. There was no obvious visual relationship seen
between CA4P dose and fall in kinetic parameters (Table 4). Three
patients (3, 10, 12) showed significant falls in Ktrans following CA4P
(outside 95% CI), and only 1 patient (12) a significant fall in
IAUGC60.
No statistically significant correlations were seen between the
continuous or categorical variables and the DCE-MRI kinetic
variables (Tables 5a and b) other than between ang-2 and Ktrans
(P¼ 0.044). Inspecting Tables 3 and 4, there are no obvious
relationships between the angiogenic profile and DCE-MRI data.
DISCUSSION
We found no obvious relationships between changes in DCE-MRI
variables and the immunohistochemical angiogenic profile. This
suggests immunohistochemical analysis of patients’ tumours is
unlikely to be useful in predicting response to VDA therapy. There
was enormous variability seen both in the DCE-MRI kinetic
variables and the immunohistochemistry. It is difficult to know
whether the variability is related to the MRI and immunohisto-
chemical techniques or is due to specific tumour characteristics
that are of interest to us ie vascular maturity.
The variability of CD34 and CD105 MVD is consistent with
previous studies. Mean microvessel density has been correlated
with risk of metastasis, prediction of efficacy of anticancer therapy,
and prognosis in a variety of tumour types (Des Guetz et al, 2006;
Gadducci et al, 2006; Zhao et al, 2006; Barresi et al, 2007; Calvin
et al, 2007; Gulubova and Vlaykova, 2007; Kavantzas et al, 2007;
Trivella et al, 2007). The PCI results agree with Eberhard’s data
(Eberhard et al, 2000). We have found no evidence that mature
vasculature with higher PCI responds poorly to CA4P, or that
immature CD105þ vasculature responds better. Tumours with
higher CD34 MVD may also have higher CD105þ MVD, however it
does not necessarily follow that active angiogenesis takes place.
There are a number of aspects of this study that undermine the
power of our conclusions. We obtained only small numbers of
samples with a heterogeneous mix of different tumour types.
However, our sample was limited to patients who had received
CA4P and undergone DCE-MRI. Within the ANOVA categorical
analysis especially, this greatly reduced the statistical power. Our
paraffin blocks, up to 21-year old, were taken from the primary
surgical procedure, whereas patients received CA4P during phase I
trials many years later after metastatic relapse. It is still unclear
whether antigenicity within paraffin blocks reduces over time
(Fergenbaum et al, 2004). There are also suggestions that the
angiogenic phenotype might continuously evolve from primary
tumour through to metastasis (Sullivan and Graham, 2007).
There were widespread falls in MRI kinetic variables following
CA4P, however for most patients these did not achieve statistical
significance. For some this was because the CA4P dose received
was below the threshold level for DCE-MRI detectable drug activity
of 50 mg m2 (Galbraith et al, 2003) – for others the CA4P simply
did not have the expected tumour blood flow effect. The reason for
administration of the lower CA4P doses in a few patients was the
dose escalation protocol for the phase I trial that revealed this
phenomenon. 95% CI for Ktrans change was 62.5 to þ 166.5%,
IAUGC60±80%. Conversely, taking the two separate trials
individually, in PH1/066 the lower 95% confidence limit for Ktrans
was 44% and in PH1/092 it was 76.5%. This wide DCE-MRI
parameter variability is in line with previously published data
(Padhani et al, 2002; Taylor et al, 2004, 2006). Combining DCE-
MRI data can adversely affect statistical confidence intervals due to
the slight differences in sequences and calibration methods used
(Taylor et al, 2006). There was wide intrapatient variability, patient
motion, and an estimated arterial input function. Modified
Fritz-Hansen arterial input coefficients, which are currently used,
demonstrate better reproducibility (Fritz-Hansen et al, 1996;
Taylor et al, 2007). Averaging the kinetic parameters over a whole
lesion also dilutes the effect of CA4P central vascular shutdown
because of relative sparing at the tumour periphery.
There was no obvious visual relationship between CA4P
dose and fall in MRI parameters. Most patients treated with
Table 4 Percentage change in DCE-MRI kinetic parameters 4 h following
infusion of CA4P
Patient
ID
CA4P Dose
(mg m2)
% Change Ktrans
post-CA4P
% Change IAUGC60
post-CA4P
04 40 63.27 15.66
13 15.02 186.00
18 45 22.91 8.38
19 26.53 17.99
20 39.71 31.94
23 30.32 30.03
24 36.51 29.43
01 52 29.56 12.26
06 65.75 146.30
07 7.38 23.81
10 67.14 58.92
02 68 30.61 19.23
05 1.59 7.32
11 0.35 17.02
17 111.84 15.44
03 88 75.20 57.65
09 58.02 58.26
16 33.01 1.88
12 114 65.49 90.21
14 20.00 13.87
15 93.46 82.38
Statistically significant positive or negative values in bold. There is no obvious visual
relationship between CA4P dose and fall in kinetic parameters, or correlation with
vascular markers. There are three missing patients: 08 CA4P dose too low
(5 mg m2), 21 WF no data available, 22 EH severe motion artefact – data unusable.
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450 mg m2 show reductions in MRI variables, and examining
those patients’ results in Table 4 there is clearly no correlation,
confirmed statistically. Several patients received lower, possibly
inactive doses of CA4P. A threshold relationship for DCE-MRI
detectable CA4P activity, with patients receiving 450 mg m2
exhibiting greater parameter falls has previously been demon-
strated (Galbraith et al, 2003; Rustin et al, 2003).
Microvessel density does not reflect the functional properties of
vessels, including permeability, which contribute to DCE-MRI
variables. Studies reporting correlation between MRI variables and
MVD have therefore found only moderate associations (Su et al,
2003; Tuncbilek et al, 2004). Several studies (Buckley et al, 1997;
Stomper et al, 1997; Su et al, 2003) show conflicting data relating
immunohistochemical expression with DCE-MRI data. The
different analysis methods used may have affected the results.
Hawighorst et al (1998) showed that MRI parameters were better
indicators of patient survival than MVD or VEGF.
The significant correlation between ang-2 and Ktrans is probably
a statistical quirk due to the number of variables investigated.
However, it might be explained as: angiopoietins are involved in
the angiogenic switch (Ahmad et al, 2001; Tanaka et al, 2003).
Ang-1 stabilises vessels by maintaining pericyte coverage; ang-2
promotes pericyte removal, which in the presence of VEGF
facilitates the angiogenic response and in the absence of VEGF
induces vessel regression (Moon et al, 2006; Bach et al, 2007; Shim
et al, 2007; Winter et al, 2007). Depending on the tumour model,
stabilisation of blood vessels by ang-1 may either promote tumour
angiogenesis or reduce tumour growth (Metheny-Barlow and Li,
2003). Wang (Wang et al, 2007) has shown ang-2 correlates with
active angiogenesis in human colorectal carcinomas, and that ang-
2 also correlates with VEGF. Thus, unstable immature ang-2
expressing vasculature undergoing neoangiogenesis is probably
more susceptible to the effects of VDAs and thus detectable by
DCE-MRI.
In conclusion, there was wide intrapatient variability in
angiogenic profile expression and DCE-MRI kinetic variable
changes following CA4P. There was no obvious correlation
between falls in MRI variables and vascular markers, however
sample numbers were small. Immunohistochemical analysis
of patients’ tumours is unlikely to be useful in predicting
response to VDA therapy. This was an exploratory study, which
we hoped would suggest some leads for further analysis.
Although one could postulate that this study should be expanded
to look at larger patient numbers and use fresh tumour samples
from a homogeneous group, such a study is unlikely ever to be
performed.
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